Pfizer offers for sale entire residual shareholding in Haleon

In a notice to the London Stock Exchange, Pfizer (PFE) announced that it intends to sell, in aggregate, approximately 662M ordinary shares in Haleon plc (HLN), representing approximately 7.3% of Haleon’s issued share capital and representing Pfizer’s entire residual shareholding in Haleon, pursuant to the offering and the share buyback, or collectively, the disposal. “Pfizer has no residual holding of Ordinary Shares in the form of American depositary shares in Haleon and there will be no sale of any Ordinary Shares in the form of American depositary shares in Haleon,” the company noted. BofA Securities, Citigroup Global Markets Limited, and Goldman Sachs International are acting as joint global coordinators and joint bookrunners, Barclays and Deutsche Numis are acting as joint bookrunners, and J.P. Morgan, Morgan Stanley, RBC Capital Markets and Independence Point Securities are acting as co-managers.